TranQuill™ Sling Snoreplasty for Snoring and Mild Obstructive Sleep Apnea:
| Status: | Completed |
|---|---|
| Conditions: | Insomnia Sleep Studies, Pulmonary, Pulmonary |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 22 - Any |
| Updated: | 9/12/2018 |
| Start Date: | February 2014 |
| End Date: | August 2014 |
TranQuill™ Sling Snoreplasty for Snoring and Mild Obstructive Sleep Apnea: A Single-arm, Pilot Study for Safety and Effectiveness
The purpose of this study is to assess the safety and effectiveness of TranQuillTM Sling (a
suture or thread used in surgery that is knotless) in snoreplasty (surgery procedure) for the
treatment of snoring and mild OSA in adult subjects. The TranQuill Sling Snoreplasty (QSS) is
a procedure where the suture will be inserted into the soft palate tissues for the treatment
of snoring and/or mild obstructive sleep apnea. Soft palate tissues are tissues in the back
of the roof of the mouth.
The research results will be used to provide data on feasibility (strengths and weaknesses),
safety, performance, and effectiveness data for the Surgical Specialties, Inc as a therapy
for snoring and/or mild obstructive sleep apnea. The TranQuillTM Sling is approved by the
U.S. Food and Drug Administration (FDA). The TranQuillTM Sling is used in all types of
surgery that involved deep tissues in the body.
The investigator in charge of the study is Dr. Boyd Gillespie. MUSC and Dr. Gillespie receive
financial support from Surgical Specialties, Inc. to conduct the study. MUSC is the only
place that this study will be conducted. For this research study the investigators plan to
enroll a total of up to 20 subjects at the Medical University of South Carolina.
suture or thread used in surgery that is knotless) in snoreplasty (surgery procedure) for the
treatment of snoring and mild OSA in adult subjects. The TranQuill Sling Snoreplasty (QSS) is
a procedure where the suture will be inserted into the soft palate tissues for the treatment
of snoring and/or mild obstructive sleep apnea. Soft palate tissues are tissues in the back
of the roof of the mouth.
The research results will be used to provide data on feasibility (strengths and weaknesses),
safety, performance, and effectiveness data for the Surgical Specialties, Inc as a therapy
for snoring and/or mild obstructive sleep apnea. The TranQuillTM Sling is approved by the
U.S. Food and Drug Administration (FDA). The TranQuillTM Sling is used in all types of
surgery that involved deep tissues in the body.
The investigator in charge of the study is Dr. Boyd Gillespie. MUSC and Dr. Gillespie receive
financial support from Surgical Specialties, Inc. to conduct the study. MUSC is the only
place that this study will be conducted. For this research study the investigators plan to
enroll a total of up to 20 subjects at the Medical University of South Carolina.
Study Methodology:
Subject Recruitment. Twenty subjects will be recruited from the MUSC Snoring Clinics as well
as public information seminars held in the greater Charleston area. Attempts will be made to
recruit both a gender and racially diverse study population.
Subject Screening. Subjects who are potentially eligible for the trial include patients who
seek treatment chronic snoring disruptive to their bed-partner. Patients will require a
pre-treatment assessment with a Watch-PAT home sleep study device to rule-out moderate and
severe sleep apnea. Patients must have a regular bed-partner to participate in order to
capture study outcomes.
Inclusion Criteria. Potential subjects must meet the following inclusion criteria:
- Age ≥ 22 years (no upper limit)
- Regular bed-partner
- Chronic, disruptive snoring according to bed-partner
- Snoring, upper airway resistance syndrome, or mild obstructive sleep apnea (AHI ≤ 15;
lowest O2 saturation ≥ 85%) on home sleep testing with Watch-PAT
- No prior surgical treatment for snoring or OSAS other than nasal surgery
- Willing and capable of providing informed consent
Exclusion Criteria.
- Age < 22 years
- No regular bed-partner
- Intermittent or occasional snoring
- Moderate-to-severe obstructive sleep apnea (AHI ≥ 16; Lowest O2 sat <85%) or evidence of
central apnea (≥ 10% of apneic events) on home sleep testing with Watch-PAT
- BMI ≥ 32 kg/m2
- Modified Mallampati 3 or 4
- Tonsil Grade 3 or 4
- Significant nasal obstruction (> 50% of nasal airway diameter on one side)
- Previous palatal surgery (cleft palate; uvulopalatopharyngoplasty; uvulectomy; Pillar
implants; Somnoplasty)
- Current cigarette smoker (≥ 1 cigarette per day)
- Known history of coronary artery disease or stroke
- Chronic obstructive pulmonary disease (COPD)
- Diabetes
- Major depression or non-controlled psychiatric illness
- Drug or alcohol abuse
- Untreated or poorly controlled hypertension
- Anticoagulation therapy (ex. Coumadin or Plavix; single baby aspirin per day allowable)
- History of bleeding or clotting disorder
- Another significant sleep disorder (e.g., insomnia, periodic limb movement)
- Tonsillar hypertrophy
- Chronic Obstructive Pulmonary Disease (COPD)
- Interstitial Lung Disease (ILD)
- Cystic Fibrosis
- Acute Repiratory Distress Syndrome (ARDS)
- Nasal or supraglottic obstruction on fiberoptic examination
- ASA class III ,IV, V
- Latex allergy
- Lidocaine allergy
- Pregnancy or plans to become pregnant Note: women of childbearing potential must
demonstrate a negative pregnancy test upon enrollment and/or be using an acceptable form
of birth control (OCPs; IUD).
- Major depression or non-stabilized psychiatric disorder
- Drug or alcohol abuse
- Previous palatal or tongue surgery
- Stable or unstable angina
- CHF
- Moderate or severe valvular disease
- TIA/CVA
- Carotid stenosis or endarterectomy
- Anemia
- Room air SpO2 < 95%
- Pulmonary hypertension
- Dialysis
- Central or mixed apnea ≥ 10% of respiratory events
- Participation in another clinical study (enrolled in any concurrent study) whose
investigational plan is judged to interfere or affect any of the measures of this study
Subject Recruitment. Twenty subjects will be recruited from the MUSC Snoring Clinics as well
as public information seminars held in the greater Charleston area. Attempts will be made to
recruit both a gender and racially diverse study population.
Subject Screening. Subjects who are potentially eligible for the trial include patients who
seek treatment chronic snoring disruptive to their bed-partner. Patients will require a
pre-treatment assessment with a Watch-PAT home sleep study device to rule-out moderate and
severe sleep apnea. Patients must have a regular bed-partner to participate in order to
capture study outcomes.
Inclusion Criteria. Potential subjects must meet the following inclusion criteria:
- Age ≥ 22 years (no upper limit)
- Regular bed-partner
- Chronic, disruptive snoring according to bed-partner
- Snoring, upper airway resistance syndrome, or mild obstructive sleep apnea (AHI ≤ 15;
lowest O2 saturation ≥ 85%) on home sleep testing with Watch-PAT
- No prior surgical treatment for snoring or OSAS other than nasal surgery
- Willing and capable of providing informed consent
Exclusion Criteria.
- Age < 22 years
- No regular bed-partner
- Intermittent or occasional snoring
- Moderate-to-severe obstructive sleep apnea (AHI ≥ 16; Lowest O2 sat <85%) or evidence of
central apnea (≥ 10% of apneic events) on home sleep testing with Watch-PAT
- BMI ≥ 32 kg/m2
- Modified Mallampati 3 or 4
- Tonsil Grade 3 or 4
- Significant nasal obstruction (> 50% of nasal airway diameter on one side)
- Previous palatal surgery (cleft palate; uvulopalatopharyngoplasty; uvulectomy; Pillar
implants; Somnoplasty)
- Current cigarette smoker (≥ 1 cigarette per day)
- Known history of coronary artery disease or stroke
- Chronic obstructive pulmonary disease (COPD)
- Diabetes
- Major depression or non-controlled psychiatric illness
- Drug or alcohol abuse
- Untreated or poorly controlled hypertension
- Anticoagulation therapy (ex. Coumadin or Plavix; single baby aspirin per day allowable)
- History of bleeding or clotting disorder
- Another significant sleep disorder (e.g., insomnia, periodic limb movement)
- Tonsillar hypertrophy
- Chronic Obstructive Pulmonary Disease (COPD)
- Interstitial Lung Disease (ILD)
- Cystic Fibrosis
- Acute Repiratory Distress Syndrome (ARDS)
- Nasal or supraglottic obstruction on fiberoptic examination
- ASA class III ,IV, V
- Latex allergy
- Lidocaine allergy
- Pregnancy or plans to become pregnant Note: women of childbearing potential must
demonstrate a negative pregnancy test upon enrollment and/or be using an acceptable form
of birth control (OCPs; IUD).
- Major depression or non-stabilized psychiatric disorder
- Drug or alcohol abuse
- Previous palatal or tongue surgery
- Stable or unstable angina
- CHF
- Moderate or severe valvular disease
- TIA/CVA
- Carotid stenosis or endarterectomy
- Anemia
- Room air SpO2 < 95%
- Pulmonary hypertension
- Dialysis
- Central or mixed apnea ≥ 10% of respiratory events
- Participation in another clinical study (enrolled in any concurrent study) whose
investigational plan is judged to interfere or affect any of the measures of this study
Inclusion Criteria:
- Age ≥ 22 years (no upper limit)
- Regular bed-partner
- Chronic, disruptive snoring according to bed-partner
- Snoring, upper airway resistance syndrome, or mild obstructive sleep apnea (AHI ≤ 15;
lowest O2 saturation ≥ 85%) on home sleep testing with Watch-PAT
- No prior surgical treatment for snoring or OSAS other than nasal surgery
- Willing and capable of providing informed consent
Exclusion Criteria:
- Age < 22 years
- No regular bed-partner
- Intermittent or occasional snoring
- Moderate-to-severe obstructive sleep apnea (AHI ≥ 16; Lowest O2 sat <85%) or evidence
of central apnea (≥ 10% of apneic events) on home sleep testing with Watch-PAT
- BMI ≥ 32 kg/m2
- Modified Mallampati 3 or 4
- Tonsil Grade 3 or 4
- Significant nasal obstruction (> 50% of nasal airway diameter on one side)
- Previous palatal surgery (cleft palate; uvulopalatopharyngoplasty; uvulectomy; Pillar
implants; Somnoplasty)
- Current cigarette smoker (≥ 1 cigarette per day)
- Known history of coronary artery disease or stroke
- Chronic obstructive pulmonary disease (COPD)
- Diabetes
- Major depression or non-controlled psychiatric illness
- Drug or alcohol abuse
- Untreated or poorly controlled hypertension
- Anticoagulation therapy (ex. Coumadin or Plavix; single baby aspirin per day
allowable)
- History of bleeding or clotting disorder
- Another significant sleep disorder (e.g., insomnia, periodic limb movement)
- Tonsillar hypertrophy
- Chronic Obstructive Pulmonary Disease (COPD)
- Interstitial Lung Disease (ILD)
- Cystic Fibrosis
- Acute Repiratory Distress Syndrome (ARDS)
- Nasal or supraglottic obstruction on fiberoptic examination
- ASA class III ,IV, V
- Latex allergy
- Lidocaine allergy
- Pregnancy or plans to become pregnant Note: women of childbearing potential must
demonstrate a negative pregnancy test upon enrollment and/or be using an acceptable
form of birth control (OCPs; IUD).
- Major depression or non-stabilized psychiatric disorder
- Drug or alcohol abuse
- Previous palatal or tongue surgery
- Stable or unstable angina
- CHF
- Moderate or severe valvular disease
- TIA/CVA
- Carotid stenosis or endarterectomy
- Anemia
- Room air SpO2 < 95%
- Pulmonary hypertension
- Dialysis
- Central or mixed apnea ≥ 10% of respiratory events
- Participation in another clinical study (enrolled in any concurrent study) whose
investigational plan is judged to interfere or affect any of the measures of this
study
We found this trial at
1
site
Charleston, South Carolina 29425
Click here to add this to my saved trials
